Last updated: September 29, 2026
Zantac Maximum Strength 150 Cool Mint was a U.S. over-the-counter ranitidine hydrochloride product containing the equivalent of 150 mg ranitidine. Its commercial position is no longer based on patent exclusivity. The principal barriers are FDA approval, NDMA impurity control, product-liability exposure, and consumer substitution toward famotidine products. The historical excipient system was conventional for an immediate-release coated tablet and offers limited standalone patent value.
What is Zantac Maximum Strength 150 Cool Mint?
Zantac Maximum Strength 150 Cool Mint was marketed as an acid reducer for heartburn and related symptoms. The active ingredient was ranitidine hydrochloride, equivalent to 150 mg of ranitidine.
| Product attribute |
Historical U.S. position |
| Brand |
Zantac Maximum Strength 150 Cool Mint |
| Active ingredient |
Ranitidine hydrochloride |
| Strength |
150 mg ranitidine equivalent |
| Dosage form |
Immediate-release oral tablet |
| Route |
Oral |
| Regulatory category |
OTC H2-receptor antagonist |
| Historical sponsor/marketer |
Sanofi/Chattem-related Zantac franchise |
| FDA reference |
NDA 018703 and associated OTC labeling history |
| Current commercial status |
Ranitidine products were withdrawn from the U.S. market after FDA action in 2020 |
| Main regulatory issue |
Nitrosodimethylamine, or NDMA, impurity risk |
The product should not be confused with Zantac 360°, which contains famotidine rather than ranitidine. Zantac 360° is a separate product platform and does not restore ranitidine’s former regulatory or patent position.
What excipients are used in Zantac Maximum Strength 150 Cool Mint?
Historical U.S. labeling identifies a conventional tablet excipient system that included calcium phosphate, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, polysorbate 80, titanium dioxide, and triacetin. The Cool Mint presentation also relied on flavoring and film-coating components associated with its mint profile. The exact commercial composition should be tied to the applicable lot-specific labeling and manufacturing record. [1]
What does each excipient contribute?
| Excipient |
Primary function |
Commercial relevance |
| Calcium phosphate |
Diluent and compression aid |
Supports tablet mass and mechanical strength |
| Microcrystalline cellulose |
Diluent and dry binder |
Improves compactability and tablet robustness |
| Croscarmellose sodium |
Superdisintegrant |
Promotes rapid tablet breakup |
| Magnesium stearate |
Lubricant |
Reduces sticking during compression and ejection |
| Hypromellose |
Film former and coating polymer |
Supports coat integrity and appearance |
| Polyethylene glycol |
Plasticizer or coating aid |
Improves coating flexibility |
| Polysorbate 80 |
Wetting or formulation aid |
Supports coating and dispersion performance |
| Titanium dioxide |
Opacifier and colorant |
Provides visual uniformity |
| Triacetin |
Plasticizer |
Improves film flexibility |
| Mint flavor system |
Organoleptic modifier |
Supports differentiation and repeat purchase |
The excipient architecture is technically defensible for a conventional immediate-release tablet, but it is not difficult to reproduce. Most components are standard compendial materials with multiple suppliers. The commercial value lies in flavor acceptance, tablet performance, stability, and manufacturing consistency rather than in ingredient exclusivity.
What excipient strategy would support a ranitidine relaunch?
A viable relaunch would require an impurity-control strategy rather than a simple replication of the historic tablet. The formulation must minimize formation, introduction, and migration of nitrosamine impurities across the drug substance, excipients, packaging, and shelf life.
Which excipient risks matter most?
The highest priority would be control of:
- Nitrite and nitrate contamination in excipients and process water.
- Amine-containing or chemically reactive formulation components.
- Moisture and elevated temperature during granulation, coating, and storage.
- Packaging-related migration and extractables.
- Excipient variability across suppliers and manufacturing sites.
A modern development program would favor direct compression or a low-moisture process if dissolution and content uniformity permit. The formulation should avoid unnecessary aqueous processing and establish incoming-material limits for nitrite, nitrate, residual solvents, elemental impurities, and peroxide content.
The company would also need a stability program designed specifically around NDMA formation. Testing only the finished product at release would be inadequate. Testing should cover:
- Drug substance before formulation.
- Each high-risk excipient.
- Blend and coated tablets.
- Accelerated and long-term stability.
- Temperature excursions.
- Light exposure where relevant.
- Container-closure interaction.
- Commercial-scale process validation lots.
What formulations could create commercial differentiation?
The historical Cool Mint tablet has limited formulation differentiation. New dosage forms could create consumer and manufacturing advantages, although each would require FDA support and impurity data.
Fast-dissolving or orally disintegrating tablet
An orally disintegrating tablet could improve convenience and reduce the need for water. It would require careful control of taste masking, friability, moisture uptake, and flavor stability. Sugar alcohols, porous carriers, and ion-exchange taste-masking systems could improve mouthfeel but may increase hygroscopicity or manufacturing complexity.
Chewable tablet
A mint-flavored chewable tablet could build on the Cool Mint consumer proposition. The main technical risks would be grittiness, aftertaste, tablet hardness, and dose uniformity. Polyols could improve sweetness and mouthfeel, but excessive use could create gastrointestinal tolerability concerns.
Film-coated swallow tablet
A conventional film-coated tablet remains the lowest-risk platform. The commercial opportunity would depend on superior taste, packaging, tablet size, or claims supported by clinical and regulatory evidence. The historic excipient system could be modernized using lower-peroxide, lower-nitrite grades and a more robust coating process.
Liquid or sachet product
A liquid or powder-for-reconstitution product could offer rapid use but would create higher stability and packaging burdens. Water activity, preservative compatibility, flavor stability, and nitrosamine formation would require extensive evaluation. This is less attractive than a dry tablet for a relaunch.
When does Zantac ranitidine lose exclusivity?
Ranitidine’s original small-molecule patent exclusivity expired decades ago. The compound was developed by Glaxo and became subject to generic competition long before the 2019 NDMA crisis. Any original compound or basic composition patents are expired in the United States.
| Exclusivity category |
Position |
| Original ranitidine compound protection |
Expired |
| Historic formulation protection |
Expired or commercially immaterial |
| FDA small-molecule exclusivity |
Expired |
| Current brand patent moat |
None identified for the discontinued ranitidine product |
| Biosimilar exclusivity |
Not applicable |
| Generic pathway |
Abbreviated New Drug Application pathway historically relevant, subject to current FDA requirements |
A new formulation could obtain patent protection only for genuinely novel and non-obvious features, such as a defined impurity-control system, unusual dosage form, specific release profile, or manufacturing process. A simple substitution of common excipients would face a weak patentability position.
What is the Orange Book status of Zantac Maximum Strength 150 Cool Mint?
The relevant historical ranitidine product does not have a meaningful current Orange Book exclusivity position. Any former listed patents or exclusivity periods would have expired. The key commercial issue is the absence of a currently marketed FDA-approved ranitidine product following the agency’s 2020 request that manufacturers withdraw ranitidine products from the U.S. market. [2]
A new sponsor would not obtain approval merely by relying on the historical Zantac label. It would need to address current FDA expectations for nitrosamine control, drug substance quality, finished-product stability, manufacturing controls, and labeling.
Are there Paragraph IV challenges to Zantac ranitidine?
Paragraph IV litigation was historically associated with generic ranitidine products and earlier ranitidine patents. Those disputes are no longer the main competitive issue because the relevant patent estate has aged out and the U.S. ranitidine market was disrupted by the NDMA withdrawal.
A future ranitidine applicant could still use an ANDA pathway if FDA requirements were satisfied, but a Paragraph IV strategy would provide little value against expired patents. The more important regulatory issue would be whether the applicant can demonstrate acceptable nitrosamine levels and a commercially reliable supply chain.
What patent litigation affects Zantac?
The major Zantac litigation was product-liability litigation involving alleged NDMA exposure, not a current patent contest. Federal multidistrict litigation was consolidated in the Southern District of Florida as In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924. In 2022, the court excluded plaintiffs’ general-causation experts, leading to dismissal of the federal cases at issue in that proceeding. [3]
Separate state-court proceedings and settlements continued to affect former manufacturers, including GSK, Sanofi, Boehringer Ingelheim, and Pfizer. Those proceedings increase diligence requirements for any buyer, licensee, or manufacturer seeking to revive the ranitidine brand.
How strong is the patent estate for Zantac Cool Mint?
The patent estate is weak as a standalone commercial asset.
| Asset category |
Strength |
Reason |
| Ranitidine active ingredient |
Low |
Historic protection expired |
| 150 mg strength |
Low |
Conventional strength with broad prior art |
| Immediate-release tablet |
Low |
Standard dosage form |
| Cool Mint flavor |
Low |
Flavor claims are difficult to defend broadly |
| Historical excipient combination |
Low |
Common excipients and predictable functions |
| New low-NDMA formulation |
Moderate potential |
Patentability depends on unexpected technical results |
| Specialized manufacturing process |
Moderate potential |
Could protect validated impurity-control features |
| Brand and consumer recognition |
Commercial, not patent-based |
Depends on regulatory clearance and reputation recovery |
The strongest potential IP would likely focus on a defined manufacturing process that limits NDMA formation, a tightly specified excipient impurity profile, or a novel delivery system. Even then, enforceability would depend on claim scope and whether competitors can design around the formulation.
How does Zantac compare with Pepcid and Zantac 360°?
The principal commercial comparison is now between ranitidine’s former brand equity and famotidine-based products.
| Factor |
Zantac Maximum Strength 150 Cool Mint |
Zantac 360° |
Pepcid |
| Active ingredient |
Ranitidine |
Famotidine |
Famotidine |
| Drug class |
H2 antagonist |
H2 antagonist |
H2 antagonist |
| U.S. market status |
Withdrawn ranitidine product |
Marketed famotidine platform |
Marketed famotidine platform |
| Patent position |
Expired |
Primarily brand, formulation, and commercial positioning |
Primarily brand and formulation positioning |
| Main risk |
NDMA and legacy litigation |
Ordinary OTC compliance and competition |
Ordinary OTC competition |
| Generic substitution |
Historically extensive |
Famotidine generic competition |
Famotidine generic competition |
| Differentiation opportunity |
New dosage form or impurity-control technology |
Flavor, onset messaging, packaging, dosage form |
Brand recognition and dosage breadth |
The substitution risk is high because famotidine products occupy the same therapeutic category without the ranitidine-specific NDMA history. A ranitidine relaunch would need a clear clinical, regulatory, or consumer advantage to displace famotidine.
What generic entry risks exist?
Generic competition would be immediate if a ranitidine product returned to the market without enforceable new formulation claims. The active ingredient, strength, and conventional tablet form are all vulnerable to rapid copying.
The main entry risks are:
- A competing manufacturer uses a different excipient system with equivalent performance.
- A generic applicant challenges any narrow formulation patent.
- Retailers favor established famotidine products.
- FDA requirements delay approval or create additional testing costs.
- Consumer concern over ranitidine persists despite successful impurity controls.
- Product-liability exposure raises insurance and reserve requirements.
What licensing and partnership opportunities exist?
A commercial opportunity would more likely involve licensing the Zantac trademark or consumer franchise than licensing expired ranitidine patents. Potential counterparties could include:
- An OTC manufacturer with nitrosamine analytical capability.
- A contract development and manufacturing organization with low-moisture tablet production.
- A flavor-house or oral-dosage-form specialist.
- A retailer seeking a private-label acid reducer.
- A company developing a new H2-antagonist delivery system.
The most defensible transaction would combine trademark rights, a validated formulation, analytical methods, supplier controls, and regulatory data. A trademark-only transaction would carry substantial development risk.
What is the revenue exposure and commercial opportunity?
The historical Zantac franchise generated substantial global revenue before the ranitidine withdrawal, but the former sales base cannot be treated as recoverable revenue. The brand’s commercial value is constrained by the separation between Zantac recognition and ranitidine safety perception.
The strongest opportunity is a non-ranitidine Zantac platform, including famotidine tablets, chewables, or fast-dissolving products. A ranitidine-specific opportunity is higher risk and would require:
- A new FDA-compliant development program.
- Demonstrated control of NDMA across the product life cycle.
- A credible consumer safety-recovery plan.
- Contractual protection against legacy liabilities.
- A formulation or delivery feature that supports new patent claims.
Key Takeaways
- Zantac Maximum Strength 150 Cool Mint was a ranitidine 150 mg immediate-release tablet.
- Its historic excipients were conventional and provide little standalone patent protection.
- Ranitidine’s original compound and basic formulation exclusivity have expired.
- The product was withdrawn from the U.S. market after FDA action concerning NDMA.
- A new ranitidine product would face regulatory and liability barriers rather than meaningful legacy patent barriers.
- A low-NDMA excipient and manufacturing strategy could support new patents, but only if the technical results are non-obvious and reproducible.
- Famotidine products, including Zantac 360° and Pepcid, are the principal commercial substitutes.
- The more attractive opportunity is likely a famotidine-based Zantac platform rather than a ranitidine relaunch.
FAQs
Is Zantac Maximum Strength 150 Cool Mint the same as Zantac 360°?
No. The former contained ranitidine. Zantac 360° contains famotidine.
Can a company launch a generic version of Zantac Cool Mint?
A company would need FDA approval and compliance with current nitrosamine-control requirements. Expired patents would not prevent entry, but regulatory and liability risks remain material.
Can mint flavoring be patented in a Zantac tablet?
A flavor alone usually provides weak protection. Stronger claims would require a novel combination with measurable advantages, such as improved masking, stability, or patient adherence.
Are ranitidine products biosimilar products?
No. Ranitidine is a synthetic small molecule. Products would use generic-drug pathways, not biosimilar pathways.
What is the best commercial replacement for Zantac Maximum Strength 150 Cool Mint?
A famotidine-based tablet, chewable, or orally disintegrating product is the most practical replacement because it avoids the ranitidine-specific NDMA issue while retaining the H2-antagonist positioning.
References
-
U.S. National Library of Medicine. (n.d.). Zantac 150 Maximum Strength ranitidine hydrochloride tablet, film coated: Drug label. DailyMed.
-
U.S. Food and Drug Administration. (2020, April 1). FDA requests removal of all ranitidine products from the market. https://www.fda.gov
-
United States District Court for the Southern District of Florida. (2022). In re Zantac (Ranitidine) Products Liability Litigation, MDL No. 2924.
-
U.S. Food and Drug Administration. (2023). Nitrosamine impurities in medications: Guidance and regulatory updates. https://www.fda.gov
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov
